# ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

> **NCT06439433** · PHASE2 · COMPLETED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade 2
- Papillomavirus Infections
- p16 Protein

## Interventions

- **DRUG:** Aminolaevulinic acid (500-mg bottle)
- **DRUG:** Aminolaevulinic acid (750-mg bottle)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06439433
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-31
- **Primary completion:** 2023-12-20
- **Final completion:** 2024-03-06
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439433, "ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06439433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*